Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
-
Publication number: 20130052128Abstract: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.Type: ApplicationFiled: February 11, 2011Publication date: February 28, 2013Inventors: Charles S. Craik, Krishna Sai Duriseti, David H. Goetz
-
Publication number: 20130052130Abstract: Disclosed are general and “substantially pure” branched discrete polyethylene glycol constructs useful in attaching to a variety of biologically active groups, for example, preferential locators, as well as biologics like enzymes, for use in diagnostics, e.g. imaging, therapeutics, theranostics, and moieties specific for other applications. In its simplest intermediate state, a branched discrete polyethylene glycol construct is terminated at one end by a chemically reactive moiety, “A”, a group that is reactive with a biologic material that creates “A”, which is a biologically reactive group, connected through to a branched core (BC) which has attached at least two dPEG-containing chains, indicated by the solid line, , having terminal groups, which can be charged, non-reactive or reactable moieties and containing between about 2 and 64 dPEG residues.Type: ApplicationFiled: August 30, 2012Publication date: February 28, 2013Applicants: UNIVERSITY OF WASHINGTON, QUANTA BIODESIGN, LTD.Inventors: Paul D. Davis, D. Scott Wilbur
-
Publication number: 20130052129Abstract: The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest.Type: ApplicationFiled: August 27, 2012Publication date: February 28, 2013Applicant: The General Hospital CorporationInventors: David R. Elmaleh, Alan J. Fischman, Timothy M. Shoup
-
Patent number: 8383081Abstract: Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a carrier such as a polymer, nanoparticle, complex or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing cell death of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate.Type: GrantFiled: May 28, 2010Date of Patent: February 26, 2013Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg, Chien-Hsing Chang
-
Patent number: 8383083Abstract: One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds.Type: GrantFiled: June 30, 2011Date of Patent: February 26, 2013Assignee: University of Western OntarioInventors: Duncan H. Hunter, Mustafa Janabi
-
Publication number: 20130039852Abstract: Methods of making bispecific binding complexes and nanopolymers coupled to detection and/or therapeutic agents are disclosed. Also disclosed are methods of using such bispecific binding complexes and nanopolymers for detecting and treating cells.Type: ApplicationFiled: October 4, 2012Publication date: February 14, 2013Applicant: NORTHEASTERN UNIVERSITYInventor: NORTHEASTERN UNIVERSITY
-
Publication number: 20130039849Abstract: The present invention features a polypeptide, such as an antibody produced by the hybridoma SAM-6 and its use in the treatment and diagnosis of neoplasms.Type: ApplicationFiled: March 23, 2012Publication date: February 14, 2013Applicant: PATRYS LIMITEDInventors: HEINZ VOLLMERS, Hans-Konrad Müller-Hermelink
-
Publication number: 20130039851Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.Type: ApplicationFiled: July 9, 2012Publication date: February 14, 2013Inventor: Edward T. Maggio
-
Publication number: 20130039850Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention is also directed to methods for producing human sequence antibodies.Type: ApplicationFiled: July 9, 2012Publication date: February 14, 2013Applicant: GENPHARM INTERNATIONAL, INC.Inventors: Nils LONBERG, Robert M. KAY, Dianne M. FISHWILD
-
Publication number: 20130034492Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: September 7, 2012Publication date: February 7, 2013Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20130034493Abstract: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.Type: ApplicationFiled: July 25, 2012Publication date: February 7, 2013Inventors: Beat A. Imhof, Marijana Miljkovic-Licina, Philippe Hammel
-
Publication number: 20130022539Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: ApplicationFiled: June 14, 2012Publication date: January 24, 2013Applicant: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Publication number: 20130024956Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20130022540Abstract: A method for delivering a biologic to a human, comprising administering said biologic parenterally into the perispina! space of said human without direct intrathecal injection and positioning said human in a Trendelenburg position.Type: ApplicationFiled: July 23, 2012Publication date: January 24, 2013Applicant: TACT IP LLCInventor: Edward Lewis Tobinick
-
Publication number: 20120328513Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: June 20, 2012Publication date: December 27, 2012Applicant: Abbott Biotherapeutics Corp.Inventors: Debbie Law, Kurt Gish
-
Publication number: 20120321556Abstract: Disclosed herein are methods and compositions comprising interferon-? (IFN-?) and anti-CD74 or anti-HLA-DR antibodies. In preferred embodiments, the IFN-? increases the expression of CD74 and/or HLA-DR in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 or anti-HLA-DR antibodies. The compositions and methods are of use to treat diseases involving CD74+ and/or HLA-DR+ cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.Type: ApplicationFiled: August 6, 2012Publication date: December 20, 2012Applicants: IMMUNOMEDICS, INC., CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGYInventors: Jack D. Burton, Rhona Stein, David M. Goldenberg
-
Publication number: 20120321555Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: ApplicationFiled: April 30, 2012Publication date: December 20, 2012Applicants: University of Tennessee Research Foundation, Elan Pharmaceuticals, Inc.Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José W. Saldanha
-
Publication number: 20120321557Abstract: Based on an anti-ICAM3 antibody obtained by immunizing a mouse with BaF3 cells having artificially over-expressed ICAM3, a chimeric antibody has been successfully prepared which exerts cytotoxic actions, including both a proliferation-suppressing activity and an ADCC activity, on a blood cancer cell line, and which exerts a tumor regression activity in vivo.Type: ApplicationFiled: February 25, 2011Publication date: December 20, 2012Applicant: FORERUNNER PHARMA RESEARCH CO., LTD.Inventor: Naoki Kimura
-
Publication number: 20120315216Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, and treatment of solid tumor stem cells.Type: ApplicationFiled: July 24, 2012Publication date: December 13, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Michael F. Clarke, Rui Liu
-
Publication number: 20120308478Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.Type: ApplicationFiled: November 11, 2010Publication date: December 6, 2012Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan
-
Publication number: 20120308479Abstract: To gain a better understanding of brain tumor angiogenesis, new techniques for isolating brain endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from brain ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed genes that were specifically elevated in tumor-associated brain endothelium. These results confirm that neoplastic and normal endothelium in human brains are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.Type: ApplicationFiled: July 9, 2012Publication date: December 6, 2012Applicants: THE JOHNS HOPKINS UNIVERSITY, GENZYME CORPORATIONInventors: Stephen MADDEN, Clarence WANG, Brian P. COOK, John LATERRA, Kevin WALTER
-
Publication number: 20120308480Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.Type: ApplicationFiled: August 14, 2012Publication date: December 6, 2012Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
-
Publication number: 20120308477Abstract: The present invention relates to a method of treating a subject having a cancer in a body cavity characterized in that it comprises the steps of: administering in said body cavity of the subject radiolabeled binding molecules which bind to an antigen expressed by cancerous cells; washing the body cavity to remove unbound radiolabeled molecules. The present invention also relates to a body cavity perfusing system for carrying out said method.Type: ApplicationFiled: May 30, 2011Publication date: December 6, 2012Inventors: Vincent BOUDOUSQ, Isabelle Navarro-Teulon, Jean-Pierre Pouget, Andre Pelegrin
-
Publication number: 20120301394Abstract: The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.Type: ApplicationFiled: May 24, 2012Publication date: November 29, 2012Applicant: VIB VZWInventors: Kiavash Movahedi, Damya Laoui, Steve Schoonooghe, Geert Raes, Patrick De Baetselier, Jo Van Ginderachter, Nick Devoogdt, Tony Lahoutte
-
Publication number: 20120301395Abstract: The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment of cancer. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.Type: ApplicationFiled: August 7, 2012Publication date: November 29, 2012Applicant: ALPER BIOTECH, LLCInventor: Ozge ALPER
-
Patent number: 8318160Abstract: The present invention relates to the treatment of IL13 dependent neoplastic disorders comprising the administration of novel anti-IL13 antibodies. The invention also includes diagnosing such tumors or cancer using the antibodies of the present invention to detect overexpression of IL13 in the patient.Type: GrantFiled: January 14, 2010Date of Patent: November 27, 2012Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Matthew Moyle
-
Patent number: 8318133Abstract: The sensitivity and specificity of the optical modality can be enhanced by the use of highly absorbing compounds as contrast agents. Novel macrocyclic cyanine and indocyanine bioconjugates that absorb and emit light in the near infrared region of electromagnetic spectrum are disclosed. These compounds are especially useful for endoscopic, localized photoacoustic, and sonofluorescence imaging, detection and therapy of tumors and other abnormalities.Type: GrantFiled: November 2, 2010Date of Patent: November 27, 2012Assignee: Washington University in St. LouisInventors: Samuel Achilefu, Yunpeng Ye
-
Publication number: 20120294800Abstract: The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase.Type: ApplicationFiled: November 18, 2010Publication date: November 22, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Siang-Yo Lin, Joseph R. Bertino, Chen-Yong Lin
-
Publication number: 20120294799Abstract: The invention relates to Anti-TEM 1 anti-bodies or antigen-binding fragments thereof, yeast libraries comprising the same, and prophylactic, diagnostic, and therapeutic methods using the same.Type: ApplicationFiled: November 12, 2010Publication date: November 22, 2012Inventors: Nathalie Scholler, Aizhi Zhao, Donald Siegel, George Coukos
-
Publication number: 20120282177Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, skin cancer and thyroid cancer.Type: ApplicationFiled: November 2, 2010Publication date: November 8, 2012Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Publication number: 20120282176Abstract: Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.Type: ApplicationFiled: April 18, 2012Publication date: November 8, 2012Applicant: Roche Glycart AGInventors: Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umaña
-
Publication number: 20120282175Abstract: Methods to improve the success of cancer therapies that target the human folate receptor 1 are provided. Kits comprising reagent useful in the methods are further provided.Type: ApplicationFiled: March 30, 2012Publication date: November 8, 2012Applicant: ImmunoGen, Inc.Inventors: Christina N. Carrigan, Kathleen R. Whiteman, Gillian Payne, Sharron Ladd
-
Publication number: 20120282174Abstract: Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.Type: ApplicationFiled: September 15, 2010Publication date: November 8, 2012Inventors: Irving L. Weissman, Ravindra Majeti, Arash Ash Alizadeh, Mark P. Chao
-
Publication number: 20120282173Abstract: An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers.Type: ApplicationFiled: August 17, 2010Publication date: November 8, 2012Applicant: FORERUNNER PHARMA RESEARCH CO., LTD.Inventor: Naoki Kimura
-
Patent number: 8303931Abstract: The present invention pertains to a three compartment structured polymer nanoparticle (core-shell-corona) for multimodal imaging with specificity for cells or cellular components, thus enabling more advanced diagnostic approaches and targeted therapy on the cellular level without the use of additional biologically active materials.Type: GrantFiled: February 19, 2007Date of Patent: November 6, 2012Assignee: TOPASS GmbHInventors: Ulrich Pison, Bernd-Reiner Paulke, Silvia Pietschmann, Regis Cartier, Lutz Kaufner
-
Patent number: 8303960Abstract: The invention provides a radiolabeled affibody molecule comprising a fragment of an IgG-binding domain of protein A from Staphylococcus aureus, a bifunctional linker, and a radiolabel comprising 18F or 76Br, wherein the bifunctional linker links the fragment and the radiolabel. The affibody molecule binds with high affinity to select receptors, which are over-expressed in certain cancers. Since the radionuclides emit a positron, the in vitro and in vivo binding characteristics of the radiolabeled affibody can be assessed using diagnostic imaging.Type: GrantFiled: February 27, 2008Date of Patent: November 6, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jacek Capala, Dale O. Kiesewetter, Gabriela Kramer-Marek, Sang Bong Lee
-
Publication number: 20120276000Abstract: A method of inhibiting tumour angiogenesis in an individual, the method comprising administering to the individual an inhibitor of CLEC14A. The inhibitor may be an antibody, an siRNA molecule, an antisense molecule, or a ribozyme.Type: ApplicationFiled: September 3, 2010Publication date: November 1, 2012Inventors: Roy Bicknell, Xiaodong Zhuang, Manuela Mura
-
Publication number: 20120276002Abstract: Provided are a contrast agent for optical imaging, a use thereof and an apparatus using the same. The contrast agent for optical imaging of the present disclosure allows optical imaging without requiring a fluorophore or a luminophore. As a result, the optical images can be acquired without changing the physicochemical properties of a substrate. The contrast agent for optical imaging of the present disclosure may be used as an optical/nuclear bimodal imaging contrast agent for many applications, and allows radiation therapy as well as monitoring of a therapeutic effect thereof through optical imaging at the same time. Further, when a fluorophore is attached thereto, light emission may be enhanced without energy input from outside since light is emitted from the fluorophore, thereby increasing luminescence intensity and improving tissue penetration.Type: ApplicationFiled: October 22, 2010Publication date: November 1, 2012Applicant: Kyungpook National University Industry-Academic Cooperation FoundationInventors: Jeong Soo Yoo, Jeong Chan Park
-
Publication number: 20120276001Abstract: A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a metal ion, such as an ion of 90Y, 111In or 177Lu; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate. A method of therapeutic treatment of a mammal involving administration of the pharmaceutical composition is also described.Type: ApplicationFiled: May 21, 2012Publication date: November 1, 2012Applicant: Nordion (Canada) IncInventors: Zoltan Kovacs, Garry E. Kiefer, Corinne Bensimon, A. Dean Sherry, Gyula Tircso, Cara Ferreira
-
Publication number: 20120269723Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: July 5, 2010Publication date: October 25, 2012Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Guy Georges, Alexander Haas, Eike Hoffman, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
-
Publication number: 20120263644Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.Type: ApplicationFiled: April 13, 2012Publication date: October 18, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventor: Scott C. Kachlany
-
Publication number: 20120258041Abstract: The invention provides antibodies that preferentially bind to iC3b relative to C3b. These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of diseases associated with deposits of the fragment.Type: ApplicationFiled: April 6, 2012Publication date: October 11, 2012Inventors: Guriqbal S. Basi, Robin Barbour
-
Publication number: 20120258040Abstract: The invention provides compounds and methods for the ex vivo or in vivo expansion of NK T cells, CD1d-reactive T cells, and J?Q+ T cells, and the modulation of their activities. These compounds and methods have diagnostic and therapeutic applications.Type: ApplicationFiled: March 19, 2012Publication date: October 11, 2012Applicants: Beth Israel Deaconess Medical Center, Inc, The General Hospital Corporation, Dana Farber Cancer InstituteInventors: Mark A. Exley, Samuel B. Wilson, Steven P. Balk
-
Publication number: 20120258039Abstract: The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.Type: ApplicationFiled: February 6, 2012Publication date: October 11, 2012Inventors: Daniela Gast, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krüger, Silke Wolterink, Sandra Lüttgau, Ulrich Mõbius, Yi Li
-
Publication number: 20120251441Abstract: The present invention comprises a new combination or association of pharmacologically active substances and/or non-drug treatments for chronic systemic diseases such as cancer. According to the present invention, the combination or association of substances and/or non-drug treatments is used to treat cancer, clinical problems associated to cancer and adverse side effects related to substances and/or treatments used to fight this illness. The components of the combination or association of substances, the biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance and/or treatment with antineoplastic properties can be jointly or simultaneously or consecutively or sequentially administered in an appropriate form, according to their chemical properties, and with the use of the most suitable procedures, and also in the most therapeutically effective dose and use.Type: ApplicationFiled: December 15, 2009Publication date: October 4, 2012Inventor: Iseu da Silva Nunes
-
Publication number: 20120244069Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: May 7, 2012Publication date: September 27, 2012Applicant: GENMAB A/SInventors: Janine SCHUURMAN, Catharina Emanuele Gerarda HAVENITH, Paul PARREN, Jan G. J. VAN DE WINKEL, Denise Leah WILLIAMS, Jørgen PETERSEN, Ole BAADSGAARD
-
Patent number: 8273328Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.Type: GrantFiled: November 30, 2011Date of Patent: September 25, 2012Assignee: Roche GlycArt AGInventors: Pablo Umaña, Ekkehard Mössner
-
Publication number: 20120237442Abstract: The present invention concerns compositions and use of multivalent and/or multispecific antibodies or immunoconjugates, preferably made by the dock-and-lock technique. The antibodies or immunoconjugates may comprise a first and second polypeptide, each comprising VH and VL domains in series, wherein the first and second polypeptides bind to each other, wherein a VH domain on one polypeptide binds to a complementary VL domain on the other polypeptide to form an antigen binding site, wherein VH and VL domains on the same polypeptide do not bind to each other and wherein one polypeptide is attached to the amino terminal end of a CH1 domain and the other polypeptide is attached to the amino terminal end of a CL domain. The carboxyl terminal end of the CH1 domain may be attached to a CH2-CH3 domain. The antibodies or immunoconjugates are of use to treat a wide variety of diseases.Type: ApplicationFiled: May 25, 2012Publication date: September 20, 2012Applicant: IBC PHARMACEUTICALS, INC.Inventors: Edmund A. Rossi, David M. Goldenberg, Chien-Hsing Chang
-
Publication number: 20120230913Abstract: Provided herein, inter alia, are protein dispersions comprising dense protein nanoclusters and methods of making the. Upon dilution, the clusters may reversibly dissociate into native protein molecules with high biological activity. The viscosities of the nanocluster dispersions may be sufficiently low to allow small-volume subcutaneous injections.Type: ApplicationFiled: March 9, 2012Publication date: September 13, 2012Applicant: Board of Regents, The University of Texas SystemInventors: Keith P. Johnston, Jennifer A. Maynard, Andrea Miller, Brian Wilson, Thomas M. Truskett, Ameya Borwankar, Aileen Dinin
-
Publication number: 20120230911Abstract: TNF-? binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-? are provided. Binding proteins have high affinity for TNF-? and neutralize TNF-? activity. A binding protein can be a full-length antibody or a TNF-?-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-? binding proteins are useful for detecting TNF-? and for inhibiting TNF-? activity, including in a human subject suffering from a disease or disorder in which TNF-? activity is detrimental.Type: ApplicationFiled: December 8, 2011Publication date: September 13, 2012Applicant: ABBOTT LABORATORIESInventors: Chung-ming HSIEH, Carrie L. GOOGREAU, Sahana BOSE, Achim MOELLER, Tariq GHAYUR